biomedical sciences research institute - Research - University of Ulster

Book Chapters:Hölscher C (2008) Functional roles of Theta and Gamma oscillations in the association and dissociation of neuronalnetworks in primates and rodents. Chapter 7, in: Information Processing by Neuronal Populations, Hölscher and Mink(Eds)., Cambridge University Press, ISBN 978-0-521-87303-1Hölscher C (2008) How could populations of neurons encode information?. Chapter 1, in: Information Processing byNeuronal Populations, Hölscher and Mink (Eds)., Cambridge University Press, ISBN 978-0-521-87303-1Dr Jenny WorthingtonLecturer in Biomedical SciencesContact Details:T: +44 (0)28 70323541j.worthington@ulster.ac.ukDr Worthington’s main research interests include:Tumour microenvironment:Our recent research in this area has utilised the dorsal skin flap model to observe blood vessel patterning in tumoursafter treatment with chemotherapy agents. We aim to exploit these changes to develop new treatment regimensfor cancer therapy.Gene Therapy:With our collaborators in Queens University, Belfast, we have used transcriptional regulation and novel deliveryvector design to optimise delivery of iNOS to solid tumours. This protein produces nitric oxide which is extremelytoxic to tumour cells.Apoptosis:A new research project, involving Gillian Browne (PhD student) has identified a new transcription factor which isimportant in controlling apoptosis in breast and prostate cancer. We aim to develop this project further, examininghow high levels of this protein can affect the response of tumour cells to various cancer therapies.Publications:Adams C, McCarthy H, Coulter J, Worthington J, Murphy C, Robson T, Hirst DG;Nitric oxide synthase gene therapyenhances the toxicity of cisplatin in cancer cells; Journal of Gene Med e-pub. (2008)Butterworth KT, McCarthy HO, Devlin A, Ming L, Robson T, McKeown SR, Worthington J; Hypoxia selects for invasive,androgen independent and apoptosis-resistant LNCaP cells; International Journal of Cancer, 123: 760-768, 2008Coulter J, McCarthy HO, Worthington J, Robson T, Scott SD, Hirst DG; Enhancement of the synthetic CArGpromoter by radiation and hypoxia; Gene Therapy, 15: 495-503, 2008Marginol L, Robson T, McCarthy HO, Worthington J, Murray M, Hollywood D, Lawler M, Hirst DG; The tissueplasminogen activator gene promoter: a novel tool for radiogenic gene therapy? Journal of Gene Med, 10: 1032-1038, 2008O’Rourke M, Ward C, Worthington J, McKenna J, Valentine A,Robson T, Hirst DG, McKeown SR; Evaluation ofthe anti-angiogenic potential of AQ4N; Clinical Cancer Research, 14: 1502-1509, 2008Wilson C, Scullin P, Worthington J, Seaton A, Maxwell P, O’Rourke D, Johnston PG, McKeown SR, Wilson RH, O’Sullivan37